Figure 1
77 year old male with multifocal bronchoalveolar cell carcinoma on erlotinib (Tarceva) showing marked interval response to therapy with decrease in size of right peri hilar mass. A. Infiltrative consolidative opacity involving the peri hilar region and the medial aspect of the right lower lobe. B. After 2 cycles of therapy with Tarceva there is significant reduction in the tumor burden with minimal residual opacity in the medial aspect of the right lower lobe. Fibrosis due to post treatment changes in the RLL.